Login to Your Account



Axovant move SAPS value; intepirdine guillotine means answerin’ for nelotanserin

By Randy Osborne
Staff Writer

Monday, January 8, 2018
in_the_clinic.jpg

Ilise Lombardo, clinical research head of Axovant Sciences Ltd., said the firm’s ongoing efforts will “certainly be informed” by the late-stage clinical work with approved pimavanserin (Nuplazid, Acadia Pharmaceuticals Inc.) as tests proceed with similarly 5HT2A-targeting nelotanserin. “There is good information, certainly, in the pimavanserin study,” which used one of the same measures Axovant deployed: the Scale for the Assessment of Positive Symptoms in PD (SAPS-PD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription